Review of the Manitoba cohort of patients with hereditary angioedema with normal C1 inhibitor
Abstract Background Hereditary angioedema with normal C1 inhibitor (HAE-nC1 INH) is a rare, underappreciated condition characterized by recurrent subcutaneous angioedema. The underlying pathophysiology and diagnostic criteria continues to evolve. There is a significant overlap between HAE-nC1 INH an...
Main Authors: | Lundy McKibbin, Colin Barber, Chrystyna Kalicinsky, Richard Warrington |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-11-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-019-0381-y |
Similar Items
-
Review of icatibant use in the Winnipeg Regional Health Authority
by: George Cai, et al.
Published: (2020-11-01) -
Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom
by: Hilary J. Longhurst, et al.
Published: (2018-08-01) -
Treatment of patients with hereditary angioedema with the c.988A>G (p.Lys330Glu) variant in the plasminogen gene
by: Konrad Bork, et al.
Published: (2020-02-01) -
Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight: findings from the Icatibant Outcome Survey, a cohort observational study
by: Teresa Caballero, et al.
Published: (2018-03-01) -
Optimum Use of Acute Treatments for Hereditary Angioedema: Evidence-Based Expert Consensus
by: Hilary Longhurst
Published: (2018-03-01)